Last updated on August 4, 2026 · Originally published March 9, 2017
Crack a black peppercorn and two different kinds of chemistry arrive at once. The heat is piperine, an alkaloid that has nothing to do with the cannabinoid part of this story. Underneath it sits a woody, resinous smell, and one of the main molecules carrying that aroma binds a cannabinoid receptor.
That molecule is beta-caryophyllene, and it is the reason the tidy line between terpenes and cannabinoids does not quite hold. Terpenes are supposed to be the smell. Cannabinoids are supposed to be the ones that act on the endocannabinoid system. This one is filed under the first heading and behaves like the second.
Why that matters
In 2008, a group at the Swiss Federal Institute of Technology showed that beta-caryophyllene binds selectively to the cannabinoid receptor type 2 and produces anti-inflammatory effects in mice through it. They called it the first dietary cannabinoid.
The selectivity is the whole story. CB1 receptors are abundant in the brain and mediate most of what THC does to you. CB2 is associated more with immune signalling and peripheral tissue, though it also turns up in the nervous system, particularly where there is inflammation. Beta-caryophyllene activates CB2 without meaningfully touching CB1, which is why no amount of black pepper has ever made anyone high.
For a compound found in oregano, this is a strange thing to be true.
What researchers think it does
The literature on beta-caryophyllene is large and uneven, and it helps to know where the weight actually sits.
Inflammation and pain form the centre of gravity. This is the most coherent body of work and the area where the mechanism and the results agree with each other. Across multiple rodent models, beta-caryophyllene has reduced inflammatory signalling and pain-related behaviour, often with evidence pointing at CB2. A 2025 mouse study of cannabidiol and beta-caryophyllene together in chronic inflammatory pain found the combination outperformed either compound alone, with less neuroinflammation and an antidepressant effect alongside the analgesia.
The brain-and-behaviour research is more speculative. Animal work has looked at anxiety-like and depressive-like behaviour, neuroinflammation, cognitive decline, neuropathic pain and substance-seeking. Some of it is genuinely interesting. None of it establishes that a cultivar high in beta-caryophyllene will change anyone’s mood or thinking.
Everything else is early. Colitis, liver injury, metabolic dysfunction, skin inflammation, adjunctive cancer work. The breadth gets cited as though it were depth. It is mostly cells and rodents given isolated beta-caryophyllene at pharmacological doses.
A 2026 study added weight to the CB2 case without quite closing it. Researchers gave mice with an experimental model of multiple sclerosis a sesquiterpene-rich cannabis essential oil, in which beta-caryophyllene was the dominant constituent alongside humulene and caryophyllene oxide. The oil reduced neuroinflammation, improved motor recovery and produced antidepressant-like effects. Blocking CB2 removed the benefit; blocking CB1 did not. That is strong evidence for a CB2-mediated effect of the oil. It is not proof that beta-caryophyllene alone produced it.
What has actually been tested in people
Not much, but more than nothing, and the details are worth having.
A crossover study in 24 healthy adults tested a single 100 mg oral dose and measured what reached the bloodstream. An eight-week randomised trial gave 100 mg daily to 52 women with obesity and food-addiction scores; food-addiction scores fell further than with placebo, though the study was small and did not establish beta-caryophyllene as a weight-loss treatment. Another eight-week trial gave 126 mg daily to 66 people with H. pylori infection. It did not eradicate the infection or shift the breath-test or histological measures, although nausea, epigastric pain and one inflammatory marker improved. A completed but apparently unpublished Phase 2 trial tested a 20% topical preparation, with and without capsaicin, for knee osteoarthritis; no results are posted in the registry.
Small studies, mixed results, several with commercial sponsors. But look at the doses: the published oral studies used 100 to 126 milligrams of isolated compound, taken deliberately.
That is the number to hold onto, because it is nowhere near what anyone gets from a meal or a joint.
The dietary cannabinoid problem
The phrase is accurate. Beta-caryophyllene is a permitted food additive, it occurs throughout ordinary cooking, and it activates a cannabinoid receptor. Every part is true.
It is also doing a great deal of promotional work. Binding a receptor is not the same as producing an effect you would notice, and the gap between the trial doses above and incidental dietary exposure is not a rounding error. The compound that gets studied at 100 mg in a capsule and the compound in your oregano are chemically identical and practically different. Our dietary cannabinoid piece goes further into where the phrase came from.
Where it sits in the entourage argument
The study that found cannabis terpenes do not alter THC’s activity at CB1 and CB2 — published, memorably, as Absence of Entourage — included beta-caryophyllene in its panel.
But that experiment asked whether terpenes change what THC does. Beta-caryophyllene does not need to. It goes to the receptor itself, with or without a cannabinoid present, which makes it a poor test case for the entourage question and an unusually good one for the argument that terpenes are worth studying individually. They are not a coordinated team. They are a chemically diverse set of molecules grouped largely by their biosynthetic origin, and there is no reason to assume they will behave alike — in combination studies, some improve a preparation and others make it worse.
The shape of the molecule
Briefly, because it explains a recurring confusion on lab reports.
Beta-caryophyllene is a sesquiterpene: fifteen carbons, C₁₅H₂₄, 204.36 g/mol. Its skeleton is a nine-membered ring fused to a cyclobutane, a four-carbon square that plants rarely build and chemists find awkward to make.
The naming problem is the useful part. Alpha-caryophyllene is not a variant of this compound. It is humulene, a separate molecule with an eleven-membered ring, frequently listed on the same certificate of analysis. Unqualified “caryophyllene” means the beta form.
What survives processing
Beta-caryophyllene boils at around 262°C. Myrcene boils near 167°C, ocimene and limonene around 176°C.
Those numbers are not thresholds — compounds evaporate steadily well below their boiling points — but they indicate something real. Beta-caryophyllene is half again as heavy as the monoterpenes and considerably less volatile, which can make it more persistent through drying, curing, decarboxylation and some extraction methods.
That is a tendency rather than a guarantee. Airflow, time, temperature, oxidation and the extraction method all have a say. But where the lighter compounds go first, what remains shifts toward the heavier woody and spicy end, which is one reason processed material often smells different from the flower it started as.
Air poses a separate problem. Over time some beta-caryophyllene oxidizes into caryophyllene oxide, a distinct oxygenated compound that becomes more prominent as material ages.
What it is actually used for
Three different things, worth keeping apart.
As a flavour and fragrance ingredient, it is entirely established and has been for decades. Foods, spices, cosmetics, cleaning products.
In cannabis, it is a common native constituent and frequently one of the most prominent sesquiterpenes on a certificate of analysis. It is also sold as an isolate and added to formulated terpene blends for vapes and edibles.
As a therapeutic, it is experimental. Oral supplements, topical preparations, and drug-development work aimed mainly at inflammation and pain. Human pharmacokinetic work confirms that oral beta-caryophyllene reaches the bloodstream, and that formulation makes a substantial difference to how much. Efficacy is another question.
Where it stands
Beta-caryophyllene has one of the strongest mechanistic cases among the major cannabis terpenes and still falls well short of established clinical benefit. The receptor is identified. The mechanism holds up when tested against antagonists. The preclinical results are reasonably consistent. The human trials are few, small, and dosed far above anything cannabis delivers.
What sets it apart from the rest of this hub is not proof of a useful effect. It is a defined receptor target and a comparatively coherent body of preclinical work — which is a real distinction, and not the one it usually gets sold on.
For the wider context, see our guide to cannabis terpenes.
Reviewed by Nani Frenkel, Chief Editor
Updated August 2, 2026. This article was substantially rewritten and expanded. The account of CB2 selectivity has been corrected, as has the description of the molecule’s ring structure. New material covers the hierarchy of preclinical evidence, the human trials conducted to date and their doses, the “dietary cannabinoid” claim, thermal stability relative to the monoterpenes, and current commercial and experimental uses.
Research for this article was compiled using DeepWeed, T&T’s cannabis research database — explore the underlying studies there.
Sources
- Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA. 2008;105(26):9099–9104. doi:10.1073/pnas.0803601105
- Booth JK, Page JE, Bohlmann J. Terpene synthases from Cannabis sativa. PLoS ONE. 2017;12(3):e0173911. doi:10.1371/journal.pone.0173911
- Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis Cannabinoid Res. 2019;4(3):165–176. doi:10.1089/can.2019.0016
- Cannabidiol and beta-caryophyllene: chronic inflammatory pain. Pharmacol Res. 2025. doi:10.1016/j.phrs.2025.107987
- A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in an experimental autoimmune encephalomyelitis model through CB2-mediated signalling. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158068
- The effect of β-caryophyllene on food addiction and its related behaviors: a randomized, double-blind, placebo-controlled trial. Appetite. 2022 (full citation to confirm)
- Randomized, double-blind, placebo-controlled trial of β-caryophyllene 126 mg/day in Helicobacter pylori infection. 2019 (full citation to confirm)
- Topical 20% beta-caryophyllene alone and in combination with 0.025% capsaicin for pain caused by osteoarthritis of the knee. ClinicalTrials.gov NCT03152578
- Acute changes in thermal pain response following single oral dose of beta-caryophyllene. ClinicalTrials.gov NCT04794205
